Alphabet's subsidiary focusing on life sciences and health technologiesVerily, earlier announced it would close its medical device division and lay off related employees. While the number of employees affected was not disclosed, the layoffs signal Alphabet's continued focus on artificial intelligence and data infrastructure as it adjusts its investment priorities.
Verily has long been considered one of the most promising "moonshot" businesses of Google's parent company, with research areas covering smart medical solutions for diabetes, robotic surgery technology, and other innovative medical applications.
However, according to an internal letter, Verily has made the difficult decision to no longer continue investing in the production of medical devices and will no longer provide related technical support.
The results are still representative, but not in line with the long-term direction
Verily CEO Stephen Gillett stated in a statement that while the medical device business is not a primary source of profit for Alphabet, its achievements continue to contribute to medical research and clinical care. For example, the Dexcom G7 continuous glucose monitoring system (CGM) launched in partnership with Dexcom, and the Stargazer VNRC drug screening platform, which has facilitated clinical testing for over 7800 patients, continue to have an impact on medical technology.
However, since Alphabet began laying off 2023 employees in 1.2 and adjusting its investment priorities, it has gradually reallocated more resources to AI, the cloud, and data-driven precision medicine. The announcement of the closure of its medical device division is clearly an extension of this development strategy.
Focusing on the future of precision health and AI
Stephen Gillett emphasized that Verily will return to its core mission, focusing on precision health and continuously advancing medical research and clinical applications through artificial intelligence and data analytics. This means that Verily will become more of a provider of medical data and AI platform services rather than a traditional medical hardware manufacturer.
As the global healthcare industry continues to digitize, AI-assisted diagnosis, medical record integration, and personalized health management have become key areas of focus for technology companies and startups. For Alphabet, while Verily has abandoned some hardware development, the healthcare ecosystem built through data and AI may play a more strategic role in the future health technology market.
